AI
Monday, December 09, 2024 2:37:06 PM
The first 35 patients in the neoadjuvant trial were enrolled between October 2016 and September 2017. That was quite a while ago.
See the following figure which is about the data on the 25 rGBM patients? But there is an extra column and it is the first column which is the data on patient #7 from the 35 patients. I suspect that Merck enrolled another 25 rGBM patients in 2020 with the objective in making a better comparison with the data from the combo trial in 2020.
Can we conclude that DCVax L could/did enhance Pembros MOA based on the additional 25?
100%. We can have a sense from the following figure. More importantly, for the combo trial, we know the root cause that affects the efficacy. It is the immunosuppression from TAMs.
Recent NWBO News
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
